Interleukin-30 receptor complex

The term “Interleukin-30 receptor complex” is not a standard molecular target; rather, it refers to the group of proteins that function as receptors for **Interleukin-30 (IL-30)**, which is the p28 subunit of the heterodimeric cytokine interleukin-27 (IL-27)[1][2][3][4]. IL-30 as a cytokine can signal independently or form complexes with other proteins, and its receptor engagement is complex and context-dependent. The IL-30 receptor complex generally includes **gp130 (glycoprotein 130)** and **WSX-1 (IL-27 receptor alpha)**[4]. IL-30 may also signal in combination with other partners such as soluble IL-6 receptor alpha (sIL-6Rα) or cytokine-like factor 1 (CLF1)[4]. In immune cells, especially human monocytes and macrophages, signaling through the IL-30 \"receptor\" triggers JAK/STAT pathway activation—primarily through STAT1 and STAT3[4]. The functional activities of IL-30 receptor signaling include modulation of inflammation (regulating Th1 and Th17 responses), as well as involvement in cancer biology, especially in breast and prostate cancer progression[2][3]. Critical note: The concept of a discrete “Interleukin-30 receptor complex” is not well-defined in major scientific nomenclature. The generally accepted terminology instead describes receptor subunits (gp130, WSX-1/IL-27Rα) or interactions with soluble receptor molecules, rather than a singular, canonical receptor complex for IL-30. There appears to be a misconception in the query, as “Interleukin-30 receptor complex” per se is not generally referenced as a single drug target in the literature[4]. Instead, it is more accurate to refer to “gp130 + WSX-1 heterodimer (the IL-27 receptor)” as the main receptor site for IL-30, with other potential signaling modes involving sIL-6Rα or CLF-1 as co-receptors or alternative partners[1][4].

Activation of JAK/STAT signaling pathway (especially via STAT1 and STAT3); Signal transduction via WSX-1 (IL-27 receptor alpha) and gp130 components; Antagonism of IL-27 and IL-6 signaling through competitive receptor binding